Blood test may predict immunotherapy success in advanced cancers
NCT ID NCT06227728
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study is observing 50 adults with advanced cancers (lung, breast, colorectal, gastric, or liver) who are starting immunotherapy. Researchers want to see if changes in ctDNA (bits of tumor DNA in the blood) can predict early whether the treatment is working. They will also check if standard markers like PD-L1 and TMB help predict response. The goal is to find better ways to monitor treatment without relying only on scans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical Genetics Institute
NOT_YET_RECRUITINGHo Chi Minh City, Vietnam
-
University of Medicine and Pharmacy at HCMC
RECRUITINGHo Chi Minh City, Hồ Chí Minh, Vietnam
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- A stitch in time: could a device make abdominal closure safer?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts